Eisai Listed as a Global 100 Most Sustainable Corporation for the Sixth Time Jan 19, 2022 16:36 HKT/SGT Read More
エーザイ、DIAN-TUが実施する優性遺伝アルツハイマー病に対する抗MTBRタウ抗体E2814の臨床第II/III相試験に最初の被験者が登録 Jan 19, 2022 10:00 JST Read More
Eisai's Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study Jan 19, 2022 09:06 HKT/SGT Read More
Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022 Jan 18, 2022 13:00 HKT/SGT Read More
Senior Management Increases Shareholdings in EC Healthcare With Strong Confidence in the Group's Future Development Jan 17, 2022 20:18 HKT/SGT Read More
Eisai to Present Abstracts on Lenvatinib at 2022 ASCO Gastrointestinal Cancers Symposium Jan 17, 2022 10:44 HKT/SGT Read More
Eisai to Launch Digital Too "Cogmate" in Taiwan and Hong Kong for Self-Assessment of Brain Performance (Brain Health) Jan 13, 2022 12:26 HKT/SGT Read More
中国抗体荣获“第六届金港股”评选中“最佳中小市值公司”、“最佳CEO”奖项及“2021新浪财经金麒麟最佳港美股上市公司”评选中“最具成长潜力上市公司”奖项 Jan 11, 2022 16:57 HKT/SGT Read More
中國抗體榮獲「第六屆金港股」評選中「最佳中小市值公司」、「最佳CEO」獎項及「2021新浪財經金麒麟最佳港美股上市公司」評選中「最具成長潛力上市公司」獎項 Jan 11, 2022 16:56 HKT/SGT Read More
SinoMab Awarded the "Best Small and Mid-Cap Company" and "Best CEO" in the Selection of the "6th Hong Kong Golden Stocks Awards" and the "Listed Company with the Most Growth Potential" in the Selection of "2021 Sina Finance Golden Unicorn Best Hong Kong and US Listed Companies" Jan 11, 2022 16:55 HKT/SGT Read More